Expanded Access to ABBV-706
Latest Information Update: 31 Jan 2026
At a glance
- Drugs ABBV 706 (Primary)
- Indications Neuroendocrine tumours; Small cell lung cancer; Solid tumours
- Focus Expanded access; Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 05 Jan 2026 New trial record